FI943565A - Uusia veren hyytymistä estäviä polypeptidejä, niiden valmistus ja niitä sisältävä farmaseuttinen koostumus - Google Patents

Uusia veren hyytymistä estäviä polypeptidejä, niiden valmistus ja niitä sisältävä farmaseuttinen koostumus Download PDF

Info

Publication number
FI943565A
FI943565A FI943565A FI943565A FI943565A FI 943565 A FI943565 A FI 943565A FI 943565 A FI943565 A FI 943565A FI 943565 A FI943565 A FI 943565A FI 943565 A FI943565 A FI 943565A
Authority
FI
Finland
Prior art keywords
preparation
pharmaceutical composition
composition containing
novel anticoagulant
anticoagulant polypeptides
Prior art date
Application number
FI943565A
Other languages
English (en)
Swedish (sv)
Other versions
FI943565A0 (fi
Inventor
Reinhard Fleer
Alain Fournier
Jean-Dominique Guitton
Gerard Jung
Patrice Yeh
Original Assignee
Rhone Poulenc Rorer Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rhone Poulenc Rorer Sa filed Critical Rhone Poulenc Rorer Sa
Publication of FI943565A publication Critical patent/FI943565A/fi
Publication of FI943565A0 publication Critical patent/FI943565A0/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C07K14/765—Serum albumin, e.g. HSA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Diabetes (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
FI943565A 1992-01-31 1994-07-29 Uusia veren hyytymistä estäviä polypeptidejä, niiden valmistus ja niitä sisältävä farmaseuttinen koostumus FI943565A0 (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9201066A FR2686901A1 (fr) 1992-01-31 1992-01-31 Nouveaux polypeptides antithrombotiques, leur preparation et compositions pharmaceutiques les contenant.
PCT/FR1993/000087 WO1993015200A1 (fr) 1992-01-31 1993-01-28 Polypeptides antithrombotiques, antagonistes de la liaison du vwf aux plaquettes et/ou au sous-endothelium

Publications (2)

Publication Number Publication Date
FI943565A true FI943565A (fi) 1994-07-29
FI943565A0 FI943565A0 (fi) 1994-07-29

Family

ID=9426193

Family Applications (1)

Application Number Title Priority Date Filing Date
FI943565A FI943565A0 (fi) 1992-01-31 1994-07-29 Uusia veren hyytymistä estäviä polypeptidejä, niiden valmistus ja niitä sisältävä farmaseuttinen koostumus

Country Status (7)

Country Link
EP (1) EP0625199A1 (fi)
JP (1) JPH07503369A (fi)
CA (1) CA2126092A1 (fi)
FI (1) FI943565A0 (fi)
FR (1) FR2686901A1 (fi)
NO (1) NO942840L (fi)
WO (1) WO1993015200A1 (fi)

Families Citing this family (130)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5900476A (en) * 1986-05-30 1999-05-04 The Scripps Research Institute Therapeutic domains of van Willebrand factor
US5824307A (en) 1991-12-23 1998-10-20 Medimmune, Inc. Human-murine chimeric antibodies against respiratory syncytial virus
FR2719593B1 (fr) * 1994-05-06 1996-05-31 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur préparation et composition pharmaceutique les contenant.
GB9526733D0 (en) 1995-12-30 1996-02-28 Delta Biotechnology Ltd Fusion proteins
US6926898B2 (en) 2000-04-12 2005-08-09 Human Genome Sciences, Inc. Albumin fusion proteins
MXPA03007619A (es) 2001-02-27 2003-12-04 Maxygen Aps Nuevas moleculas similares a interferon beta.
ES2500918T3 (es) 2001-12-21 2014-10-01 Human Genome Sciences, Inc. Proteínas de fusión de albúmina e interferón beta
US7132100B2 (en) 2002-06-14 2006-11-07 Medimmune, Inc. Stabilized liquid anti-RSV antibody formulations
US7425618B2 (en) 2002-06-14 2008-09-16 Medimmune, Inc. Stabilized anti-respiratory syncytial virus (RSV) antibody formulations
EP2316487B1 (en) 2003-04-11 2014-06-11 MedImmune, LLC Recombinant IL-9 antibodies & uses thereof
US7393534B2 (en) 2003-07-15 2008-07-01 Barros Research Institute Compositions and methods for immunotherapy of cancer and infectious diseases
WO2005047334A1 (en) 2003-11-13 2005-05-26 Hanmi Pharmaceutical. Co., Ltd. Igg fc fragment for a drug carrier and method for the preparation thereof
WO2005058961A2 (en) 2003-12-12 2005-06-30 Amgen Inc. Antibodies specific for human galanin, and uses thereof
WO2006034292A2 (en) 2004-09-21 2006-03-30 Medimmune, Inc. Antibodies against and methods for producing vaccines for respiratory syncytial virus
AU2006214121B9 (en) 2005-02-15 2013-02-14 Duke University Anti-CD19 antibodies and uses in oncology
KR100754667B1 (ko) 2005-04-08 2007-09-03 한미약품 주식회사 비펩타이드성 중합체로 개질된 면역글로불린 Ｆｃ 단편 및이를 포함하는 약제학적 조성물
JP5047947B2 (ja) 2005-05-05 2012-10-10 デューク ユニバーシティ 自己免疫疾患のための抗ｃｄ１９抗体治療
US8217147B2 (en) 2005-08-10 2012-07-10 Macrogenics, Inc. Identification and engineering of antibodies with variant Fc regions and methods of using same
EA015860B1 (ru) 2005-10-13 2011-12-30 Хьюман Дженом Сайенсиз, Инк. Способы лечения аутоиммунных заболеваний при использовании антагониста нейтрокина-альфа
CN103071209A (zh) 2005-11-17 2013-05-01 周吉尼克斯股份有限公司 用无针注射递送粘稠制剂
EP1816201A1 (en) 2006-02-06 2007-08-08 CSL Behring GmbH Modified coagulation factor VIIa with extended half-life
EP2540741A1 (en) 2006-03-06 2013-01-02 Aeres Biomedical Limited Humanized anti-CD22 antibodies and their use in treatment of oncology, transplantation and autoimmune disease
US8268347B1 (en) 2006-10-24 2012-09-18 Aradigm Corporation Dual action, inhaled formulations providing both an immediate and sustained release profile
CN101861168B (zh) 2007-05-07 2014-07-02 米迪缪尼有限公司 抗-icos抗体及其在治疗肿瘤、移植和自身免疫病中的应用
BRPI0811526A2 (pt) 2007-05-14 2017-05-16 Biowa Inc uso de um anticorpo monoclonal, quimérico, humanizado ou humano que liga o il-5r, anticorpo anti-il-5r isolado, e, epítopo isolado de il-5r alfa
EP1997830A1 (en) 2007-06-01 2008-12-03 AIMM Therapeutics B.V. RSV specific binding molecules and means for producing them
SG10201407388XA (en) 2007-08-29 2015-01-29 Sanofi Aventis Humanized anti-cxcr5 antibodies, derivatives thereof and their uses
EP2050764A1 (en) 2007-10-15 2009-04-22 sanofi-aventis Novel polyvalent bispecific antibody format and uses thereof
JP5490714B2 (ja) 2007-11-28 2014-05-14 メディミューン，エルエルシー タンパク質製剤
US8092804B2 (en) 2007-12-21 2012-01-10 Medimmune Limited Binding members for interleukin-4 receptor alpha (IL-4Rα)-173
EP2245064B1 (en) 2007-12-21 2014-07-23 Medimmune Limited BINDING MEMBERS FOR INTERLEUKIN-4 RECEPTOR ALPHA (IL-4Ralpha)
EP2273880B1 (en) 2008-04-28 2014-12-31 Zogenix, Inc. Novel formulations for treatment of migraine
EP3173424A1 (en) 2008-05-02 2017-05-31 Novartis Ag Improved fibronectin-based binding molecules and uses thereof
WO2010015608A1 (en) 2008-08-05 2010-02-11 Novartis Ag Compositions and methods for antibodies targeting complement protein c5
US8163497B2 (en) 2008-09-07 2012-04-24 Glyconex Inc. Anti-extended type I glycosphingolipid antibody, derivatives thereof and use
CA2743469C (en) 2008-11-12 2019-01-15 Medimmune, Llc Antibody formulation
WO2010087927A2 (en) 2009-02-02 2010-08-05 Medimmune, Llc Antibodies against and methods for producing vaccines for respiratory syncytial virus
AU2010239861B2 (en) 2009-04-22 2013-07-11 Alteogen, Inc In vivo half life increased fusion protein or peptide maintained by sustained in vivo release, and method for increasing in vivo half-life using same
WO2010138555A2 (en) 2009-05-26 2010-12-02 University Of Florida Research Foundation, Inc. Small peptide expression system in mammalian cells
WO2011020024A2 (en) 2009-08-13 2011-02-17 The Johns Hopkins University Methods of modulating immune function
US8568726B2 (en) 2009-10-06 2013-10-29 Medimmune Limited RSV specific binding molecule
TR201804897T4 (tr) 2009-10-07 2018-06-21 Macrogenics Inc Fukosi̇lasyon ölçüsünün deği̇şi̇mleri̇nden dolayi geli̇şmi̇ş efektör i̇şlevi̇ sergi̇leyen fc bölgesi̇ni̇ i̇çeren poli̇pepti̇tler ve bunlarin kullanimlarina yöneli̇k yöntemler
WO2011051466A1 (en) 2009-11-02 2011-05-05 Novartis Ag Anti-idiotypic fibronectin-based binding molecules and uses thereof
CN107412737A (zh) 2010-01-19 2017-12-01 韩美科学株式会社 长效g‑csf缀合物的液体制剂
WO2011092233A1 (en) 2010-01-29 2011-08-04 Novartis Ag Yeast mating to produce high-affinity combinations of fibronectin-based binders
CN103038258B (zh) 2010-05-06 2017-02-15 诺华股份有限公司 用于治疗低密度脂蛋白相关蛋白质6(lrp6)的抗体的组合物及使用方法
AU2011249782B2 (en) 2010-05-06 2014-10-02 Novartis Ag Compositions and methods of use for therapeutic low density lipoprotein - related protein 6 (LRP6) multivalent antibodies
WO2012019061A2 (en) 2010-08-05 2012-02-09 Stem Centrx, Inc. Novel effectors and methods of use
BR112013004012B1 (pt) 2010-08-20 2021-03-23 Novartis Ag Anticorpo monoclonal isolado ou fragmento de ligação ao antígeno do mesmo ao receptor her3, seu uso e composição farmacêutica
EP2608807A1 (en) 2010-08-27 2013-07-03 Stem Centrx, Inc. Notum protein modulators and methods of use
NZ608814A (en) 2010-09-03 2015-06-26 Stem Centrx Inc Novel modulators and methods of use
RS59589B1 (sr) 2010-11-05 2019-12-31 Zymeworks Inc Dizajniranje stabilnog heterodimernog antitela sa mutacijama u fc domenu
WO2012069466A1 (en) 2010-11-24 2012-05-31 Novartis Ag Multispecific molecules
SG10201601792UA (en) 2010-12-08 2016-04-28 Stemcentrx Inc Novel modulators and methods of use
US20120171195A1 (en) 2011-01-03 2012-07-05 Ravindranath Mepur H Anti-hla-e antibodies, therapeutic immunomodulatory antibodies to human hla-e heavy chain, useful as ivig mimetics and methods of their use
SA112330278B1 (ar) 2011-02-18 2015-10-09 ستيم سينتركس، انك. مواد ضابطة جديدة وطرق للاستخدام
JP2014510730A (ja) 2011-03-16 2014-05-01 サノフイ デュアルｖ領域抗体様タンパク質の使用
WO2012170740A2 (en) 2011-06-07 2012-12-13 University Of Hawaii Biomarker of asbestos exposure and mesothelioma
WO2012170742A2 (en) 2011-06-07 2012-12-13 University Of Hawaii Treatment and prevention of cancer with hmgb1 antagonists
WO2012172495A1 (en) 2011-06-14 2012-12-20 Novartis Ag Compositions and methods for antibodies targeting tem8
CN103930440A (zh) 2011-07-01 2014-07-16 拜耳知识产权有限责任公司 松弛素融合多肽及其用途
WO2013007563A1 (en) 2011-07-08 2013-01-17 Bayer Intellectual Property Gmbh Fusion proteins releasing relaxin and uses thereof
US20130058947A1 (en) 2011-09-02 2013-03-07 Stem Centrx, Inc Novel Modulators and Methods of Use
EP2773667A1 (en) 2011-11-01 2014-09-10 Bionomics, Inc. Anti-gpr49 antibodies
US9220774B2 (en) 2011-11-01 2015-12-29 Bionomics Inc. Methods of treating cancer by administering anti-GPR49 antibodies
EP2773665A1 (en) 2011-11-01 2014-09-10 Bionomics, Inc. Antibodies and methods of treating cancer
EP2773373B1 (en) 2011-11-01 2018-08-22 Bionomics, Inc. Methods of blocking cancer stem cell growth
JP6326371B2 (ja) 2011-11-04 2018-05-16 ザイムワークス，インコーポレイテッド Ｆｃドメインにおける変異を有する安定なヘテロ二量体抗体デザイン
CN104039830A (zh) 2011-11-04 2014-09-10 诺华股份有限公司 低密度脂蛋白相关蛋白6(lrp6)-半寿期延长物构建体
SG11201402739YA (en) 2011-12-05 2014-06-27 Novartis Ag Antibodies for epidermal growth factor receptor 3 (her3) directed to domain ii of her3
EP3590538A1 (en) 2011-12-05 2020-01-08 Novartis AG Antibodies for epidermal growth factor receptor 3 (her3)
EP3330288A1 (en) 2011-12-21 2018-06-06 Novartis AG Compositions and methods for antibodies targeting factor p
US10800847B2 (en) 2012-01-11 2020-10-13 Dr. Mepur Ravindranath Anti-HLA class-IB antibodies mimic immunoreactivity and immunomodulatory functions of intravenous immunoglobulin (IVIG) useful as therapeutic IVIG mimetics and methods of their use
US20130177574A1 (en) 2012-01-11 2013-07-11 Paul I. Terasaki Foundation Laboratory ANTI-HLA CLASS-Ib ANTIBODIES MIMIC IMMUNOREACTIVITY AND IMMUNOMODULATORY FUNCTIONS OF INTRAVENOUS IMMUNOGLOBULIN (IVIg) USEFUL AS THERAPEUTIC IVIg MIMETICS AND METHODS OF THEIR USE
CN104520324A (zh) 2012-02-24 2015-04-15 施特姆森特Rx股份有限公司 Dll3调节剂及其使用方法
US9592289B2 (en) 2012-03-26 2017-03-14 Sanofi Stable IgG4 based binding agent formulations
US10064951B2 (en) 2012-03-30 2018-09-04 Hanmi Science Co., Ltd. Liquid formulation of highly concentrated long-acting human growth hormone conjugate
JP6351572B2 (ja) 2012-05-10 2018-07-04 ザイムワークス，インコーポレイテッド Ｆｃドメインに突然変異を有する免疫グロブリン重鎖のヘテロ多量体構築物
US10656156B2 (en) 2012-07-05 2020-05-19 Mepur Ravindranath Diagnostic and therapeutic potential of HLA-E monospecific monoclonal IgG antibodies directed against tumor cell surface and soluble HLA-E
AR091902A1 (es) 2012-07-25 2015-03-11 Hanmi Pharm Ind Co Ltd Formulacion liquida de un conjugado de insulina de accion prolongada
WO2014084859A1 (en) 2012-11-30 2014-06-05 Novartis Ag Molecules and methods for modulating tmem16a activities
AP2015008365A0 (en) 2012-12-05 2015-04-30 Novartis Ag Compositions and methods for antibodies targeting epo
US10981961B2 (en) 2013-03-11 2021-04-20 University Of Florida Research Foundation, Incorporated Delivery of card protein as therapy for occular inflammation
WO2014159239A2 (en) 2013-03-14 2014-10-02 Novartis Ag Antibodies against notch 3
JP6505079B2 (ja) 2013-03-29 2019-04-24 アレクシオン ファーマシューティカルズ， インコーポレイテッド 補体ｃ５を標的とする治療薬の血清半減期を増加させるための組成物及び方法
AR096601A1 (es) 2013-06-21 2016-01-20 Novartis Ag Anticuerpos del receptor 1 de ldl oxidado similar a lectina y métodos de uso
UY35620A (es) 2013-06-21 2015-01-30 Novartis Ag Anticuerpos del receptor 1 de ldl oxidado similar a lectina y métodos de uso
EP3892294A1 (en) 2013-08-28 2021-10-13 AbbVie Stemcentrx LLC Site-specific antibody conjugation methods and compositions
JP2016538318A (ja) 2013-08-28 2016-12-08 ステムセントリックス， インコーポレイテッド 新規ｓｅｚ６モジュレーターおよび使用方法
US8986691B1 (en) 2014-07-15 2015-03-24 Kymab Limited Method of treating atopic dermatitis or asthma using antibody to IL4RA
US8980273B1 (en) 2014-07-15 2015-03-17 Kymab Limited Method of treating atopic dermatitis or asthma using antibody to IL4RA
MX2016012873A (es) 2014-04-04 2017-03-07 Bionomics Inc Anticuerpos humanizados que se unen al receptor 5 acoplado a proteina g que contiene repeticion rica en leucina (lgr5).
WO2016020880A2 (en) 2014-08-07 2016-02-11 Novartis Ag Angiopoietin-like 4 antibodies and methods of use
TW201613977A (en) 2014-08-07 2016-04-16 Novartis Ag Angiopoetin-like 4 (ANGPTL4) antibodies and methods of use
MA41044A (fr) 2014-10-08 2017-08-15 Novartis Ag Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
UY36449A (es) 2014-12-19 2016-07-29 Novartis Ag Composiciones y métodos para anticuerpos dirigidos a bmp6
CA3176123A1 (en) 2015-05-19 2016-11-24 Yale University Compositions for treating pathological calcification conditions, and methods using same
EA201792561A1 (ru) 2015-06-05 2018-04-30 Новартис Аг Антитела, нацеленные на морфогенетический белок кости 9 (bmp9), и способы их применения
JOP20200312A1 (ar) 2015-06-26 2017-06-16 Novartis Ag الأجسام المضادة للعامل xi وطرق الاستخدام
KR20180035852A (ko) 2015-08-03 2018-04-06 노파르티스 아게 Fgf21-연관 장애를 치료하는 방법
PE20181368A1 (es) 2015-09-09 2018-08-27 Novartis Ag Moleculas de union a linfopoyetina estromal timica (tslp) y metodos de uso de las moleculas
MY186352A (en) 2015-09-09 2021-07-15 Novartis Ag Thymic stromal lymphopoietin (tslp)-binding antibodies and methods of using the antibodies
KR20180089510A (ko) 2015-12-18 2018-08-08 노파르티스 아게 CD32b를 표적화하는 항체 및 그의 사용 방법
BR112018014150A2 (pt) 2016-01-11 2018-12-11 Novartis Ag anticorpos monoclonais humanizados imunoestimulantes contra interleucina-2 humana, e proteínas de fusão dos mesmos
US20210198368A1 (en) 2016-01-21 2021-07-01 Novartis Ag Multispecific molecules targeting cll-1
US10745487B2 (en) 2016-03-22 2020-08-18 Bionomics Limited Method of treating cancer by administering an anti-LGR5 monoclonal antibody
JP7138567B2 (ja) 2016-04-27 2022-09-16 ノバルティス アーゲー 成長分化因子１５に対する抗体およびそれらの使用
CN109152817A (zh) * 2016-05-20 2019-01-04 瑞士奥克特珐玛公司 具有改进的药代动力学的糖基化vwf融合蛋白
EP3471759A1 (en) 2016-06-15 2019-04-24 Novartis AG Methods for treating disease using inhibitors of bone morphogenetic protein 6 (bmp6)
CN118320078A (zh) 2016-12-23 2024-07-12 诺华股份有限公司 采用抗因子XI/XIa抗体治疗的方法
IL308980A (en) 2016-12-23 2024-01-01 Novartis Ag Antibodies against factor XI and methods of their use
WO2018146594A1 (en) 2017-02-08 2018-08-16 Novartis Ag Fgf21 mimetic antibodies and uses thereof
WO2018229715A1 (en) 2017-06-16 2018-12-20 Novartis Ag Compositions comprising anti-cd32b antibodies and methods of use thereof
US20210040205A1 (en) 2017-10-25 2021-02-11 Novartis Ag Antibodies targeting cd32b and methods of use thereof
AR126019A1 (es) 2018-05-30 2023-09-06 Novartis Ag Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación
US11492409B2 (en) 2018-06-01 2022-11-08 Novartis Ag Binding molecules against BCMA and uses thereof
UY38407A (es) 2018-10-15 2020-05-29 Novartis Ag Anticuerpos estabilizadores de trem2
JP2022513626A (ja) 2018-11-26 2022-02-09 ノバルティス アーゲー Ｌｐｌ－ｇｐｉｈｂｐ１融合ポリペプチド
US20220169706A1 (en) 2019-03-28 2022-06-02 Danisco Us Inc Engineered antibodies
WO2020236792A1 (en) 2019-05-21 2020-11-26 Novartis Ag Cd19 binding molecules and uses thereof
WO2020236797A1 (en) 2019-05-21 2020-11-26 Novartis Ag Variant cd58 domains and uses thereof
WO2020242989A1 (en) 2019-05-24 2020-12-03 Sanofi Methods for treating systemic sclerosis
EP4031578A1 (en) 2019-09-18 2022-07-27 Novartis AG Entpd2 antibodies, combination therapies, and methods of using the antibodies and combination therapies
TW202124446A (zh) 2019-09-18 2021-07-01 瑞士商諾華公司 與ｅｎｔｐｄ２抗體之組合療法
WO2021202473A2 (en) 2020-03-30 2021-10-07 Danisco Us Inc Engineered antibodies
WO2022097060A1 (en) 2020-11-06 2022-05-12 Novartis Ag Cd19 binding molecules and uses thereof
AR129136A1 (es) 2022-04-26 2024-07-17 Novartis Ag Anticuerpos multiespecíficos que se dirigen a il-13 e il-18
WO2024015953A1 (en) 2022-07-15 2024-01-18 Danisco Us Inc. Methods for producing monoclonal antibodies
US11773160B1 (en) 2022-08-05 2023-10-03 Anaveon AG Immune-stimulating IL-2 fusion proteins
WO2024130158A1 (en) 2022-12-16 2024-06-20 Modernatx, Inc. Lipid nanoparticles and polynucleotides encoding extended serum half-life interleukin-22 for the treatment of metabolic disease

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992006999A1 (en) * 1990-10-17 1992-04-30 The Scripps Research Institute Therapeutic fragments of von willebrand factor
ATE120206T1 (de) * 1986-05-30 1995-04-15 Scripps Clinic Res Peptide, die die bindung des von-willebrand- faktors inhibieren.
FR2650598B1 (fr) * 1989-08-03 1994-06-03 Rhone Poulenc Sante Derives de l'albumine a fonction therapeutique
NZ237244A (en) * 1990-03-02 1992-10-28 Bio Technology General Corp Cloning and production of human von willebrand factor analogues and compositions thereof
AU1757592A (en) * 1991-03-27 1992-11-02 Scripps Research Institute, The Therapeutic fragments of von willebrand factor
WO1993000357A1 (en) * 1991-06-28 1993-01-07 Rhone-Poulenc Rorer International (Holdings) Inc. Therapeutic polypeptides based on von willebrand factor

Also Published As

Publication number Publication date
NO942840L (no) 1994-09-29
CA2126092A1 (fr) 1993-08-05
JPH07503369A (ja) 1995-04-13
WO1993015200A1 (fr) 1993-08-05
NO942840D0 (no) 1994-07-29
FR2686901A1 (fr) 1993-08-06
FI943565A0 (fi) 1994-07-29
EP0625199A1 (fr) 1994-11-23

Similar Documents

Publication Publication Date Title
FI943565A (fi) Uusia veren hyytymistä estäviä polypeptidejä, niiden valmistus ja niitä sisältävä farmaseuttinen koostumus
DE10199066I1 (de) Pharmazeutische Zusammensetzung
IL95155A0 (en) 1h-indazole-3-carboxamides,their preparation and pharmaceutical compositions containing them
IL95640A0 (en) 1-cycloalkylpiperidines,their preparation and pharmaceutical compositions containing them
IT1232677B (it) Composizione farmaceutica contenente ranitidina
DK489189A (da) Farmaceutisk praeparat
EE03111B1 (et) Glükokortikosteroidi epimeerid, nende valmistamise protsessid ja neid sisaldavad ravimpreparaadid
IL94556A0 (en) Hydroxypropylamines,their preparation and pharmaceutical compositions containing them
FI951789A (fi) Uusia taksaanijohdannaisia, niiden valmistus ja niitä sisältävät farmaseuttiset koostumukset
FI893643A (fi) Farmaceutiska kompositioner.
IL86876A0 (en) Polypeptides,their preparation and pharmaceutical composition containing them
FI961938A0 (fi) Uudet taksoidit, niiden valmistus ja niitä sisältävät farmaseuttiset valmisteet
FI960316A (fi) Oksatiolaanit, menetelmä niiden valmistamiseksi ja niitä sisältävät farmaseuttiset koostumukset
IL91709A0 (en) Substituted thienopyrans,their preparation and pharmaceutical compositions containing them
IL92326A0 (en) Substituted oxadiamino-butanes,their preparation and pharmaceutical compositions containing them
FR2636063B1 (fr) Composes phenylpyrroliques utiles en tant que medicaments, leur preparation et leur application
IL91003A0 (en) Proteins,their production and pharmaceutical compositions containing them
DK336489A (da) Farmaceutisk praeparat
IL99009A0 (en) Polypeptides,their preparation and pharmaceutical compositions containing them
IL84509A0 (en) Pyrrolo-benzimidazoles,their preparation and pharmaceutical composition containing them
IL95563A0 (en) Substituted amino-pyridines,their preparation and pharmaceutical compositions containing them
IL93479A0 (en) 1h-imidazole-1-acetamides,their preparation and pharmaceutical compositions containing them
IT1224244B (it) Composizione farmaceutica anoressizzante comprendente 5-idrossitrpofano
KR860005809A (ko) 3--1h-인다졸, 이의 제조방법 및 이들 화합물을 함유하는 약제학적 조성물
IL84126A0 (en) Factor ix-peptides,their preparation and pharmaceutical compositions containing them

Legal Events

Date Code Title Description
FD Application lapsed